PBS updates

Tecentriq (Atezolizumab)

atezolizumab 1.2 g/20 mL injection, 20 mL vial · INJECTION · PBS code 11792P

STREAMLINED

What it costs

AU$6747.37 PBS-determined price per pack

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2019-10-01.
  • • Repeats: 5.
  • • PBS program: IN.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Stage IV (metastatic) non-small cell lung cancer (NSCLC)


Initial treatment 1


Patient must be undergoing combination treatment with bevacizumab and platinum-doublet chemotherapy; AND

The condition must be non-squamous type non-small cell lung cancer (NSCLC); AND

Patient must not have previously been treated for this condition in the metastatic setting; or

The condition must have progressed after treatment with a prior targeted therapy PBS-listed for this condition; AND

Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer; AND

Patient must have a WHO performance status of 0 or 1; AND

The condition must not have evidence of an activating epidermal growth factor receptor (EGFR) gene mutation or an anaplastic lymphoma kinase (ALK) gene rearrangement in tumour material.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Stage IV (metastatic) non-small cell lung cancer (NSCLC)


Initial treatment 2


Patient must be undergoing combination treatment with bevacizumab and platinum-doublet chemotherapy; AND

The condition must be non-squamous type non-small cell lung cancer (NSCLC); AND

Patient must have a WHO performance status of 0 or 1; AND

Patient must have evidence of an activating epidermal growth factor receptor (EGFR) gene mutation or of an anaplastic lymphoma kinase (ALK) gene rearrangement in tumour material; AND

Patient must have progressive disease following treatment with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) OR an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI); AND

Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer.

Sponsor: Roche Products Pty Ltd ABN 70 000 132 865

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.